Guidance documents are prepared for FDA review staff and applicants/sponsors to provide guidelines to the processing, content, and evaluation/approval of applications and also to the design, production, manufacturing, and testing of regulated products.
Similar Posts
PDUFA VII Commitment: An Assessment of the Sentinel System (2022 to 2024)
PDUFA VII Commitment: An Assessment of the Sentinel System (2022 to 2024)IndulgeRx Brands, Inc – 703668 – 06/16/2025
New Drug/MisbrandedWithdrawn | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
This listing includes accelerated approvals (AAs) for non-malignant hematological, neurological, and other disorder indications with postmarketing trials that have been subsequently withdrawn, and are therefore, no longer FDA-approved.FDA Approves First Over-the-Counter Naloxone Nasal Spray
The U.S. Food and Drug Administration approved the first naloxone nasal spray product available without a prescription.Gina Marie Bakery of Waterbury Issues Recall of Cookies Due to Undeclared Almonds, Sesame and Food Dyes
Gina Marie Bakery of Waterbury, CT is recalling 1lb and 2 lb packages of the above-mentioned cookies because they contain undeclared allergens. People who have allergies to nuts, sesame seeds and/or food dyes run the risk of serious or life-threatening allergic reaction if they consume these producFrom Our Perspective: OMUFA – Past, Current, and Future
The OTC Monograph drug user fee program, which we refer to as “OMUFA,” is similar to our other user fee programs, such as the Prescription Drug User Fee Act (PDUFA).